ONWARD: Up-LIFT reveals ARC-EX extraordinary neurological potential vs SOC

The so-awaited full disclosure of the ARC-EX Up-LIFT pivotal study materialized yesterday with its publication in the top-tier scientific journal - Nature (access here). Whilst the top-line data reported in April 2023 already validated ARC-EX Therapy efficacy hitting 72% responder rate, the extende

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

Fashion: consumers backpedaling on sustainability due to inflation

In our recent Fashion report "Is sustainability the new luxury?", we were highlighting the green consumer paradox vis-a-vis sustainable brands. A McKinsey survey just discovered that consumers are indeed de-emphasising the importance of ESG in their purchases in an inflation-impacted world. This wo

Casino: 100/1 reverse stock split adjustment

With Casino implementing its 100 for 1 reverse stock split today, we have adjusted our PT from EUR0.024 to EUR2.4. We continue to see the New Casino as far too cash-constrained to be able to reinvest as much as needed in the business (covenant too tight from 2026 onwards) and optimise the likelihoo

Interparfums issues bonus share award.